Molecular targeted therapy of glioblastoma
E Le Rhun, M Preusser, P Roth, DA Reardon… - Cancer treatment …, 2019 - Elsevier
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …
progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH) …
Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Abstract c-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …
gene) family, and is expressed on the surfaces of various cells. Hepatocyte growth factor …
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter… - Nature, 2018 - nature.com
Pan-cancer analyses that examine commonalities and differences among various cancer
types have emerged as a powerful way to obtain novel insights into cancer biology. Here we …
types have emerged as a powerful way to obtain novel insights into cancer biology. Here we …
Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma
A Mackay, A Burford, D Carvalho, E Izquierdo… - Cancer cell, 2017 - cell.com
We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse
intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of> …
intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of> …
MET-dependent solid tumours—molecular diagnosis and targeted therapy
Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
J Fu, X Su, Z Li, L Deng, X Liu, X Feng, J Peng - Oncogene, 2021 - nature.com
This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …
Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes
M Clarke, A Mackay, B Ismer, JC Pickles… - Cancer discovery, 2020 - AACR
Infant high-grade gliomas appear clinically distinct from their counterparts in older children,
indicating that histopathologic grading may not accurately reflect the biology of these tumors …
indicating that histopathologic grading may not accurately reflect the biology of these tumors …
Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor
Low-grade gliomas almost invariably progress into secondary glioblastoma (sGBM) with
limited therapeutic option and poorly understood mechanism. By studying the mutational …
limited therapeutic option and poorly understood mechanism. By studying the mutational …
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy
PM Comoglio, L Trusolino, C Boccaccio - Nature Reviews Cancer, 2018 - nature.com
The MET oncogene encodes an unconventional receptor tyrosine kinase with pleiotropic
functions: it initiates and sustains neoplastic transformation when genetically altered …
functions: it initiates and sustains neoplastic transformation when genetically altered …
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Receptor tyrosine kinases (RTKs) are transmembrane receptors of great clinical interest due
to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK …
to their role in disease, notably cancer. Since their discovery, several mechanisms of RTK …